Metabolic reprogramming can indeed occur in cancer due to mutations in metabolic relevant genes, such as isocitrate dehydrogenases (IDH1 and IDH2) in acute myelogenous leukemia (AML) and glioblastoma [63–65] (see later in Fig. 4). This evidence concerns the gene IDH2 and acute myeloid leukemia.